首次分子学缓解的成人良好及中危急性髓系白血病中无关匹配移植与自体移植的比较
比较373例自体移植与335例10/10相容无关供者异基因移植的首次分子学缓解急性髓系白血病患者,按ELN分层。良好风险组自体移植非复发死亡率更低、总生存更优;中危1组无关供者移植无白血病生存和总生存更优;中危2组结局相同。
要点
- 良好风险组自体移植较无关供者移植非复发死亡率更低(3.7%对19%),总生存更优(83%对62%)。
- 中危1组无关供者移植较自体移植无白血病生存更优(70%对39%),总生存更优(74%对61%)。
- 中危2组自体移植与无关供者移植结局相同。
核心结论
- 良好风险患者从自体移植中获得更高获益。
- 中危2患者两种移植结局相同,中危1患者从无关供者移植中获得更高获益。
研究设计与样本
- 比较373例自体移植与335例10/10相容无关供者异基因移植的首次分子学缓解急性髓系白血病患者,按ELN分类分层。
主要发现
- 良好风险组(自体234例,无关供者70例):自体组非复发死亡率3.7%对19%(P<10^-4),复发率29%对17%(P<10^-4),无白血病生存67%对64%,总生存83%对62%(P=.008)。
- 中危1组(自体87例,无关供者172例):自体组非复发死亡率2.5%对11.8%(P=.03),复发率59%对18%(P<10^-6),无白血病生存39%对70%(P<10^-6),总生存61%对74%(P=.005)。
- 中危2组(自体52例,无关供者93例):结局相同。
- 多因素分析:良好风险组自体移植与更低非复发死亡率相关(HR: 4,P=.01),总生存更优(HR: 2.08,P=.04);中危1组无关供者移植在无白血病生存(HR: 0.36,P<10^-5)和总生存(HR: 0.53,P=.01)方面优于自体移植。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with Acute Myelogenous Leukemia have a better outcome if reaching molecular remission. We compared the outcome of 373 patients autografted and 335 patients allografted with a 10/10 compatible unrelated donor in first molecular remission. Patients were stratified using the ELN European Leukemia Net classification. ELN favorable group: (234 auto and 70 unrelated transplants). By univariate analysis, in the auto group, the Non Relapse Mortality (NRM) was lower (3.7% versus 19%; P < 10-4 ), Relapse Incidence (RI) higher (29% versus 17%, P < 10-4 ), Leukemia Free Survival (LFS) identical (67% versus 64%) and Overall Survival (OS) better than in the allogeneic group (83% versus 62%; P = .008). By multivariate analysis, autologous transplantation was associated with a lower NRM (HR: 4, P = .01) and a better OS (HR: 2.08, P = .04). ELN intermediate group 1: (87 autologous and 172 unrelated transplants). By univariate analysis, in the auto group, NRM was lower (2.5% versus 11.8%; P = .03), RI higher (59% versus 18%, P < 10-6 ), LFS lower (39% versus 70%; P < 10-6 ) and OS lower than in the unrelated donor group (61% versus 74%; P = .005). By multivariate analysis, unrelated donor was superior to autologous transplantation for LFS (HR: 0.36, P < 10-5) and OS (HR: 0.53, P = .01). ELN intermediate group 2: (52 autologous and 93 unrelated donors). The outcome was identical. We conclude that good risk patients get higher benefit from autologous transplantation. Intermediate risk 2 patients have the same outcome and Intermediate risk 1 patients get higher benefit from unrelated donor transplants.
引用
- Gorin NC, Labopin M, Pabst T, et al. Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission. Am J Hematol. 2017. PMID: 28960419. doi:10.1002/ajh.24904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。